Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Akero Therapeutics ( (AKRO) ).
On December 2, 2025, Akero Therapeutics‘ stockholders approved the company’s acquisition by Novo Nordisk A/S during a special meeting held virtually. The merger proposal and related compensation proposal received overwhelming support, with over 81% of eligible shares voted in favor. The merger is subject to customary closing conditions, including antitrust clearances, and is expected to close by the end of the year. The FTC granted early termination of the waiting period under the HSR Act, marking a significant step towards finalizing the merger.
The most recent analyst rating on (AKRO) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Akero Therapeutics stock, see the AKRO Stock Forecast page.
Spark’s Take on AKRO Stock
According to Spark, TipRanks’ AI Analyst, AKRO is a Neutral.
Akero’s stock score reflects strong technical momentum and positive corporate developments, which are key drivers. However, financial challenges with no current revenue and operational losses weigh down the overall score. The promising clinical trial results provide a potential catalyst for future growth.
To see Spark’s full report on AKRO stock, click here.
More about Akero Therapeutics
Akero Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for serious metabolic diseases. The company is known for its innovative therapies aimed at addressing unmet medical needs.
Average Trading Volume: 2,242,751
Technical Sentiment Signal: Buy
Current Market Cap: $4.48B
For an in-depth examination of AKRO stock, go to TipRanks’ Overview page.